Biology and Medicine

Abstract

Prognostic Values of Enzyme Changes in Pre and Post-Treated Pancreatic Cancer Patients

N. Sivakumar, B. Prabasheela*, R. Arivazhagan, R. Vijayalakshmi

Introduction: The extensive desmoplastic microenvironment, essential for tumor growth, invasion, metastasis, angiogenesis, immunosuppression, and chemoresistance, is thought to be the cause of PDAC's high aggressiveness. Since tumor cells' energy metabolism differs from that of normal cells and is mostly based on aerobic glycolysis, fatty acid oxidation, and glutaminolysis, it is regarded as one of the distinguishing characteristics of cancer. As a result, a deeper comprehension of the intricate molecular traits of pancreatic cancer is required. There is mounting evidence that alterations in serum enzyme levels are crucial for the initiation and spread of cancer. Before and after chemotherapy, cancer patients have a variety of biochemical serum enzyme indicators, including Lactate Dehydrogenase (LDH), Adenosine Deaminase (ADA), Gamma-Glutamyl Transferase (GGT), amylase, and lipase imbalance. The meticulous monitoring of variations in serum enzyme marker levels greatly influenced the prognosis of the disease.

Materials and methods: We have included 500 pancreatic cancer patients (test group), regardless of age or gender, who were enrolled at "The Cancer Institute" in Adyar, Chennai, Tamil Nadu between 2016 and 2020. Hospital staff, age-matched, non-alcoholic, non-diabetic, voluntary blood donors, and a total of 100 healthy volunteers served as the study's control group.

Result and discussion: Males are more likely than females to contract the sickness (3:2), and the risk rises with age (>61-80). Based on current research, it appears that aberrant metabolism leading to changes in serum enzyme levels is a significant factor in PDAC patients. Serum enzyme panel levels have shown severe abnormalities in PDAC patients (P<0.05), indicating a compromised physiological state. The level of these enzyme biomarkers significantly decreased following three consecutive rounds of chemotherapy (1st, 2nd, and 3rd), demonstrating the potential of the chemotherapy medications. According to our research, combination chemotherapy the administration of many medications is a promising treatment option for pancreatic cancer. 

Published Date: 2025-01-16; Received Date: 2023-11-07